The breast cancer drug Lynparza (olaparib) has shown promising results in a phase III trial comparing it with standard breast cancer treatment, AstraZeneca announced recently.
AstraZeneca said patients given the Lynparza tablets
a showed a "statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy."
“These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive phase III data for a PARP inhibitor beyond ovarian cancer," Sean Bohen, executive vice president of AstraZeneca's Global Medicines Development, said.
Patients were given the Lynparza tablets twice a day. A full evaluation of the data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting.
AstraZeneca touts results of breast cancer drug
Organizations in this Story
Want to get notified whenever we write about AstraZeneca Pharmaceuticals LP ?
Next time we write about AstraZeneca Pharmaceuticals LP, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts